BACKGROUND: Obesity increases the risk of cardiovascular disease, hypertension, diabetes, and other disorders. Several studies have shown that excess weight or weight gain was related to the decline of pulmonary function. This study is to find out whether pilot's age, height, body weight, body mass index(BMI) and smoking are related to the baseline measurement of pulmonary function in order to promote the healthy behavior of pilots. METHOD: The analysis was based on data from the annual physical examination of pilots which was conducted in one airlines company of Korea. This study compared the data obtained from 73 pilots in 1996 with the data in 2002. Pulmonary function(forced vital capacity (FVC), forced expiratory volume in one second (FEV1) and maximal mid expiratory flow (MMEF), peak expiratory flow (PEF)), age, height, body weight and body mass index were measured in both surveys. Multivariate analysis of variance (MANOVA) was used to examine the relationship weight gain, smoking and pulmonary function. RESULTS: According to the data from 2002, mean age, mean height, mean body weight and mean BMI of pilots were examined: 47.62 years, 171.60 cm, 70.6 Kg and 24.03 Kg/m(2). Age was significantly related to FVC, FEV1 and MMEF. Height was significantly related to FVC and FEV1. However, body weight was significantly related to PEF and MMEF. The effect of smoking on pulmonary function was not significant. Pilots who gained body weight and BMI after 7 years were not related significantly to the pulmonary function. CONCLUSION: This study shows that age, height, weight are significantly related to pulmonary function. And other studies show that weight gain is significantly related to the decline of pulmonary function, but the relationship from this study is not significant because the number of sample is not enough and healthy behaviors of most pilots are relatively well.
Body Height ; Body Mass Index ; Body Weight* ; Cardiovascular Diseases ; Forced Expiratory Volume ; Hypertension ; Korea ; Multivariate Analysis ; Obesity ; Physical Examination ; Smoke ; Smoking ; Vital Capacity ; Weight Gain

BACKGROUND: Neurologic and neuropsychologic dysfunction after cardiopulmonary bypass is frequent and can be caused by inadequate cerebral perfusion and oxygenation. A decrease of SjvO2 suggests a situation in which the oxygen supply to the brain is insufficient to meet metabolic demands. This study investigated the effects of normocapnia and hypercapnia on changes in SjvO2 and lactate levels during rewarming from hypothermic cardiopulmonary bypass. METHODS: Anesthesia was induced and maintained with bolus and continuous infusion of fentanyl, midazolam and vecuronium. Patients were assigned to a normocapnic (PaCO2: 35 - 40 mmHg, n = 10) or hypercapnic (PaCO2: 45 50 mmHg, n = 10) group during rewarming. SjvO2 and lactate levels at the jugular bulb were measured at 30, 34 and 37degrees C nasopharyngeal temperature. RESULTS: There was not a reduction in SjvO2 to < 50% in normocapnic and hypercapnic group during the rewarming period, and there was no significant difference in lactate levels at the jugular bulb. However, the hypercapnic group had a higher SjvO2 than the normocapnic group at 30, 34 and 37degrees C nasopharyngeal temperature during rewarming (P<0.05). CONCLUSIONS: Hypercapnia is more effective increasing SjvO2 than normocapnia and may contribute to the prevention of postoperative neurologic dysfunction, especially in patients having a low SjvO2.
Anesthesia ; Brain ; Cardiopulmonary Bypass* ; Fentanyl ; Humans ; Hypercapnia* ; Lactic Acid* ; Midazolam ; Neurologic Manifestations ; Oxygen* ; Perfusion ; Rewarming* ; Vecuronium Bromide

OBJECTIVES: The purpose of this study was to evaluate the long-term efficacy and safety of risperidone in the treatment of Korean schizophrenic patients. METHOD: This multicenter open label study included 116 schizophrenic patients drawn from 19 university hospitals. After a wash-out period of 1 week, the patients were treated with risperidone for 56 weeks and evaluated at 8 points:at baseline, and the 8th, 16th, 24th, 32nd, 40th, 48th, 56th weeks of treatment. The dose was started at 2mg of risperidone on day 1, and increased to 4mg on day 2, and 6mg on day 3,7 and adjusted to a maximum of 16mg/day according to the individual's clinical response. The psychiatric and neurological status of the patients was assessed by PANSS, CGI, and ESRS scales. RESULTS: Eighty-seven(75%) of 116 patients completed the 56-week trial of risperidone. Clinical improvement(as defined by a 20% of reduction in total PANSS score at end point) was shown by 92.0% of the patients. The mean dose of risperidone was 5.0mg/day in the 56 week follow-up. PANSS total scores showed significant improvements between consecutive two points at baseline, 8th, 16th, 24th, 32nd, and 48th week of treatment. CGI scores showed significant reductions between consecutive two points at baseline, 8th, 16th, 24th, and 48th week of treatment. Three PANSS factors(positive, negative, general) showed a significant improvement from the 8th week of treatment, and, after then, remained improved in the rest of the study period. ESRS showed no significant change during the 56 week trial. Laboratory parameters showed no significant changes during the course of treatment. CONCLUSIONS: This multicenter long-term open study suggests that risperidone is a antipsychotic drug with long term efficacy and safety in the treatment of schizophrenic patients.
Follow-Up Studies* ; Hospitals, University ; Humans ; Risperidone* ; Schizophrenia* ; Weights and Measures

OBJECTIVE: The purpose of this study was to investigate the efficacy and safety of risperidone in the treatment of Korean schizophrenic patients. METHOD: This multicenter open study included 377 schizophrenic patients drawn from 39 university hospitals. After a wash-out period of 1 week, the schizophrenic patients were treated with risperidone for 8 weeks and evaluated at 5 points: at baseline, and 1,2,4 and 8 weeks of treatment. The dose was increased from 2mg/day(1mg twice daily) to 6mg/day(3mg twice daily) during the first week and adjusted to a maximum of 16mg/day over the next 7 weeks according to the patient's clinical response. Medication to control extrapyramidal symptoms was permitted. The psychiatric and neurological status of the patients was assessed by PANSS, CGI, and ESRS scales. RESULTS: 343(91%) of 377 patients completed the 8-week trial period. Clinical improvement, as defined by a 20% or more reduction in total PANSS score at end point, was shown by 81.3% of patients. The predictors of response to risperidone were associated older age, shorter duration of illness, fewer previous hospitalization. Risperidone had rapid onset of action: a significant decrease of the total PANSS and three PANSS factor(positive, negative, general), and CGI was already noticed at the end of first week. For the ESRS, parkinsonism rating scores were significantly increased until week 4 comparing with baseline. Dystonia rating scores were significantly increased until week 1, and dyskinesia rating scores were not significantly changed during the study. Laboratory parameters including vital sign, EKG, hematological, and biochemical values showed no significant changes during the trial. CONCLUSIONS: This study suggests that risperidone is generally safe and effective against both the positive and negative symptoms in our group of patients.
Dyskinesias ; Dystonia ; Electrocardiography ; Hospitalization ; Hospitals, University ; Humans ; Parkinsonian Disorders ; Risperidone* ; Schizophrenia* ; Vital Signs ; Weights and Measures